

**EASTWOOD BIO-MEDICAL CANADA INC.**

#1130 - 4871 Shell Road  
Richmond, British Columbia  
V6X 3Z6

TSX-V: EBM

NEWS RELEASE

**Eastwood Bio-Medical Canada Inc. Begins Initial Discussions with Autoimmune Disease Experts**

**November 15, 2018 – Richmond, British Columbia – Eastwood Bio-Medical Canada Inc. (TSX-V: EBM) (the “Company”)** is pleased to announce that the Company has begun exploring the possibility of eventually developing products for patients of autoimmune disorders and has begun initial discussions with experts on autoimmune diseases.

“Autoimmune diseases” is a term that describes a group of diseases where the body’s immune system attacks its own tissues. Examples of autoimmune diseases include: rheumatoid arthritis, lupus, inflammatory bowel disease (IBD), multiple sclerosis (MS), Type 1 diabetes mellitus, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, and vasculitis.

The Company has recently begun accumulating an increasing number of anecdotal cases from patients of autoimmune diseases whose conditions have significantly improved both in the short and long terms after using our products. There have also been numerous reports from clients about improvements regarding their inflammation conditions generally.

Yunji Kim, President and CEO, commented, “We are intrigued and encouraged by these anecdotes. We have also noted the publication of studies and articles exploring the relationship between insulin resistance, blood glucose levels, and some autoimmune diseases. We believe it is justifiable and timely to look into the possibility of developing products that help consumers with autoimmune disorders. Continuing our long history of working with global leaders in science and medicine, we have started initial discussions with experts in this field.

However, it is important to note that at this point we have only anecdotal testimonials from clients relaying their own individual experiences. Autoimmune diseases are serious medical conditions, and we make no claims or suggestions regarding any effect our products may have. Patients, regardless of their condition, should always consult with their doctors before starting any new regime. There will have to be a long and uncertain process before we can scientifically ascertain any effect our products may have on autoimmune patients.”

**About Eastwood Bio-Medical Canada, Inc.:**

The Company is a Vancouver based company whose Eleotin brand of products provide natural sourced solutions for metabolic syndromes such as blood glucose control, obesity, and hypertension.

Eleotin was initially developed by the scientists at the Julia McFarlane Diabetes Research Center (JMDRC) at the University of Calgary in Alberta, Canada. The JMDRC is a leader in research on Type I and Type II diabetes. After the initial development by the JMDRC, research and development were continued by Eastwood Bio-Medical Research Inc., the Company, and other institutions around the world, including Tsinghua University of the People's Republic of China. Eleotin products have been endorsed by thousands of doctors and medical associations around the globe, and authorized by Advertising Standards Canada (ASC) to be marketed as the 'World's #1 Doctor Recommended Natural Source Healthy Blood Glucose Promoting Product available in Canada.'

More information on Eastwood Bio-Medical Canada Inc., can be found on the website [www.eleotin.ca](http://www.eleotin.ca).

**For further information, please contact:**

Eastwood Bio-Medical Canada Inc.  
Yunji Kim, President and Chief Executive Officer  
Telephone: (604) 247-2100

*CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. There is no assurance that the new products will produce the revenue increase the Company expects. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*